Human nasal beta‐amyloid 42 reflects cognition decline in Alzheimer’s disease

• DOI: 10.1002/alz.068779
• Publication Date: 2022-12-20T16:42:55Z
• Authors: Da Hae Jung; Gowoon Son; Shengmin Wang; Hyun Kook Lim; Cheil Moon
• Keywords: Amyloid beta; Cognitive Decline; Montreal Cognitive Assessment

Abstract Background The key in Alzheimer’s disease (AD) therapy is a timely and accurate diagnosis for prompt drug intervention. However, due to the high cost invasiveness of conventional biomarker analyses, including brain positron emission tomography (PET) imaging cerebrospinal fluid (CSF)‐based assays, easy accessibility these screening tests often hindered. There is, therefore, great need develop more accessible test using less invasive cost‐effective peripheral body biomarkers. Previous studies examined non‐quantitative expression beta‐amyloid (Aβ) normal AD patients' nasal discharge fluid. They identified higher oligomeric Aβ patients, showing correlation with cognitive decline. quantitative measurements 42 levels, full continuum, remain unknown. Here, we assessed whether quantified human levels could identify patients differentiate them from non‐AD patients. Method 161 subjects (cognitively (CN), n=32; preclinical, n=29; mild impairment (MCI), n=73; AD, n=27) underwent neuropsychological battery tests. Their samples were collected, measured via enzyme‐linked immunosorbent assay (ELISA). Result We found that second‐highest quartile (Q3) group constituted majority ( p =0.036). Q3 also outnumbered other groups most cognitively impaired all three =0.033; =0.0212; =0.0147). Conclusion Quantified strongly associated cognition measurements. Nasal suggests possibility discriminating non‐AD.